SCHEMBL5284629

SCHEMBL5284629

CC1(OCc2ccccc2)C=CC=CC1C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.39
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
SLC1A3 P43003 2/20 0.37
SLC1A2 P43004 2/20 0.37
SLC1A1 P43005 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
CYP3A4 P08684 3/20 0.36
TSHR P16473 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A3 Q01959 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
FABP7 O15540 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2331142 0.89 ALDH1A1 (0.41) ALDH1A1KMT2AMEN1SLC1A3SLC1A2
Phenylacetaldehyde SCHEMBL6378611 0.81 CYP3A4 (0.36) ALDH1A1KMT2AMEN1CYP3A4TSHR
SCHEMBL23536852 0.81 ALDH1A1 (0.37) ALDH1A1KMT2AMEN1SLC1A3SLC1A2
SCHEMBL5029772 0.80 SLC1A3 (0.37) ALDH1A1KMT2AMEN1SLC1A3SLC1A2
SCHEMBL1989127 0.80
SCHEMBL28499236 0.79 TSHR (0.35) ALDH1A1KMT2AMEN1SLC1A3SLC1A2
Hydrochloric Acid SCHEMBL9745618 0.79 SLC1A3 (0.36) ALDH1A1KMT2AMEN1SLC1A3SLC1A2
SCHEMBL7765472 0.79 KMT2A (0.36) ALDH1A1KMT2AMEN1SLC1A3SLC1A2
SCHEMBL5289688 0.78 ALDH1A1 (0.36) ALDH1A1KMT2AMEN1SLC1A3SLC1A2
SCHEMBL27999428 0.77 ALDH1A1 (0.36) ALDH1A1KMT2AMEN1SLC1A3SLC1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117794526-A Compositions and methods for antioxidants and anti-inflammatory therapeutics 阿万蒂生物科学股份有限公司 2024-03-29 CN disclosed
CN-108101870-B Preparation method of active ingredient for selectively treating glaucoma and related salt thereof 盐城师范学院 2020-03-06 CN disclosed
US-9340522-B2 Pyrazolone-derivatives and their use as PDE-4 inhibitors TAKEDA GMBH (DE) 2016-05-17 US disclosed
US-20140073672-A1 NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS TAKEDA GMBH (DE) 2014-03-13 US disclosed
WO-2007002325-A1 PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS PLEXXIKON, INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140073672-A1 NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS PDE4A, PDE3B, PDE3A ALDH1A1 344/4885KMT2A 3652/4885MEN1 3585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.